Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TELA Bio Inc TELA

Healthcare Medical Instruments & Supplies
TELA Bio, Inc. is a commercial-stage medical technology company. The Company is focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy. Its first portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), addresses unmet needs in hernia repair and abdominal wall... see more

Recent & Breaking News (NDAQ:TELA)

TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR - Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures

GlobeNewswire 3 days ago

TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy

GlobeNewswire 10 days ago

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

GlobeNewswire March 21, 2024

TELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery

GlobeNewswire March 21, 2024

MIMEDX Expands Portfolio with Fibrillar Collagen Wound Dressing

GlobeNewswire March 20, 2024

TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX

GlobeNewswire March 20, 2024

TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 29, 2024

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 23, 2024

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire January 19, 2024

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 15, 2023

TELA Bio to Take Part in Connecting the Dots

GlobeNewswire December 5, 2023

TELA Bio to Participate in Piper Sandler's 35th Annual Healthcare Conference

GlobeNewswire November 16, 2023

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 10, 2023

TELA Bio Reports Third Quarter 2023 Financial Results

GlobeNewswire November 9, 2023

TELA Bio to Announce Third Quarter 2023 Financial Results

GlobeNewswire October 26, 2023

TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase

GlobeNewswire September 18, 2023

TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

GlobeNewswire August 16, 2023

TELA Bio Reports Second Quarter 2023 Financial Results

GlobeNewswire August 9, 2023

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 4, 2023

TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference

GlobeNewswire July 26, 2023